Defective HIV proviruses and Persistent Innate Immune Activation
- Institution
- BOSTON MEDICAL CENTER, MA
- Principal investigator
- Andrew J Henderson
- Funding
- $818K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
Abstract/Summary CD4+ T cells and macrophages are infected by HIV and this infection correlates to more proinflammatory activities that drive HIV comorbidities and end organ diseases. Mechanisms that bias innate immune functions in HIV-infected cells towards chronic inflammation are poorly understood. We have demonstrated infected primary resting CD4+ T cells and macrophages harbor defective HIV-1 proviruses that, despite having deletions and mutations which attenuate provirus transcription, generate HIV-1 RNAs. The immunopathological consequences of persistent aberrant viral RNA expression have not been addressed. We hypothesize that HIV infection of CD4+ T cells and macrophages establishes a defective but transcriptionally competent proviral reservoir that expresses aberrant viral RNAs which perpetuate persistent inflammation. We will address this hypothesis in three specific aims: 1) Determine if persistent expression of cryptic HIV-1 RNAs promote innate immune activities; 2) Examine whether HIV-1 and HIV-2 have different propensities for generating intact proviral genomes and whether this influences immune activation; and 3) Determine if DNA damage response mechanisms lead to establishment of defective proviruses. Successful completion of these studies will provide general insights into the impact of HIV-1 persistence and expression in the context of CD4+ T cells and macrophages. Importantly, these studies will provide an understanding into mechanisms that contribute to HIV-1 comorbidities which persist even with antiretroviral treatments and could lead to new targets and strategies for treatments to improve the lives of people living with HIV.
Research team
- Suryaram GummuluruPI
- Andrew J HendersonPI
LOADING MOONBASE SCORE
Questions for BOSTON MEDICAL CENTER
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Boston University Medical CampusNot yet scored
Determinants of poor responsiveness to the booster dose of the RTS,S malaria vaccine in African children
James Beeson · $691K · 2024–2029
- NIH · Boston University (Charles River Campus)Not yet scored
Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis
Zandrea Ambrose · $658K · 2023–2027
- NIH · Boston Medical CenterNot yet scored
Persistent HIV-1 expression and microglia dysfunction
Suryaram Gummuluru · $730K · 2021–2026